OPKO Health/OPK

$1.23

-4.28%
-
1D1W1MYTD1YMAX

About OPKO Health

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.

Ticker

OPK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Phillip Frost

Employees

3,930

Headquarters

Miami, United States

OPKO Health Metrics

BasicAdvanced
$895.63M
Market cap
-
P/E ratio
-$0.25
EPS
1.83
Beta
-
Dividend rate
$895.63M
1.82663
$2.24
$0.85
9.66M
1.547
1.219
16.506
18.674
-15.24%
-9.03%
-12.8%
-10.03%
1.037
0.715
-14.01%
44.74%
-15.58%

What the Analysts think about OPKO Health

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
245.53% upside
High $8.50
Low $1.50
$1.23
Current price
$4.25
Average price target

OPKO Health Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-36.5% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$181.9M
1.9%
Net income
$-66.4M
-21.33%
Profit margin
-36.5%
-22.8%

OPKO Health Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 2.27%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.02
-$0.03
-$0.11
-$0.09
-
Expected
-$0.08
-$0.07
-$0.10
-$0.09
-$0.10
Surprise
-73.91%
-63.62%
10%
2.27%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for OPKO Health stock?

OPKO Health (OPK) has a market cap of $895.63M as of April 13, 2024.

What is the P/E ratio for OPKO Health stock?

The price to earnings (P/E) ratio for OPKO Health (OPK) stock is 0 as of April 13, 2024.

Does OPKO Health stock pay dividends?

No, OPKO Health (OPK) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next OPKO Health dividend payment date?

OPKO Health (OPK) stock does not pay dividends to its shareholders.

What is the beta indicator for OPKO Health?

OPKO Health (OPK) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the OPKO Health stock price target?

The target price for OPKO Health (OPK) stock is $4.25, which is 245.53% above the current price of $1.23. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell OPKO Health stock

Buy or sell OPKO Health stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing